More than 90% of the protein drugs in existence are glycoproteins. For instance, many different recombinant forms of immunoglobulins are produced as therapeutic glycoprotein drugs. These glycoprotein pharmaceuticals contain complex oligosaccharide moieties whose sites of attachment, presence or absence, and relative profiles can have significant impact on therapeutic efficacy, pharmacokinetics, immunogenicity, folding, and stability of the biologic drug.
At Agilent Technologies, we have developed a comprehensive portfolio of measurement platforms for the characterization of glycoproteins and their moieties with liquid chromatography and HPLC-Chip mass spectrometry.
Our systems are optimized to provide the data you need throughout fermentation, purification, and formulation , to determine the types and relative amounts of N-linked glycosylation structures contained in a protein biologic.